Biomarin hopes long-term valrox data can stem the bleeding
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Abbott shifts to tricuspid repair
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
Aegerion’s poisoned chalice gives Amryt some distraction therapy
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
A delicate balancing act for Immunogen
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Upcoming events – Phase III data for Chiasma and Novartis
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
Asco 2019 – Abstract drop fires the starting gun
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
Asco 2019 – Guardant and Grail square up
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
A tale of two eyes as Meiragtx sees a clearer path forward than Gensight
As Meiragtx wows investors with its gene therapy for a cause of blindness, continuing lack of clarity around Gensight’s GS010 prompts more questions than answers.
Myovant punished for success
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.